KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables (2017 - 2026)

Aquestive Therapeutics has reported Receivables over the past 9 years, most recently at $27.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 180.26% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, up 180.26%, while the annual FY2025 figure was $27.5 million, 180.26% up from the prior year.
  • Receivables for Q4 2025 was $27.5 million at Aquestive Therapeutics, up from $14.1 million in the prior quarter.
  • Over five years, Receivables peaked at $27.5 million in Q4 2025 and troughed at $6.8 million in Q4 2022.
  • A 5-year average of $13.7 million and a median of $12.1 million in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: crashed 56.35% in 2022 and later surged 180.26% in 2025.
  • Year by year, Receivables stood at $15.7 million in 2021, then crashed by 56.35% to $6.8 million in 2022, then skyrocketed by 66.39% to $11.4 million in 2023, then dropped by 13.78% to $9.8 million in 2024, then surged by 180.26% to $27.5 million in 2025.
  • Business Quant data shows Receivables for AQST at $27.5 million in Q4 2025, $14.1 million in Q3 2025, and $11.9 million in Q2 2025.